FDA Clinical Investigator Oversight Weak On Recruitment Tactics, OIG Report
This article was originally published in The Gray Sheet
Executive Summary
Protocol violations by medical device clinical investigators were cited in 78% (83/107) of official actions by FDA's Center for Devices and Radiological Health between fiscal years 1994-99, the HHS Office of Inspector General states in a report on FDA oversight of clinical investigators released June 12.